Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
2.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

3.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
4.

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

van Rooij LC, Wattjes MP, de Jong BA, van Oosten BW.

Mult Scler Relat Disord. 2017 Oct;17:54-56. doi: 10.1016/j.msard.2017.06.009. Epub 2017 Jun 29.

PMID:
29055475
5.

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Aug;264(8):1833-1836. doi: 10.1007/s00415-017-8557-1. No abstract available.

PMID:
28711999
6.

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Jun;264(6):1155-1164. doi: 10.1007/s00415-017-8509-9. Epub 2017 May 23. Review. Erratum in: J Neurol. 2017 Jul 15;:.

PMID:
28536921
7.

Real-Time Assessment of Fatigue in Patients With Multiple Sclerosis: How Does It Relate to Commonly Used Self-Report Fatigue Questionnaires?

Heine M, van den Akker LE, Blikman L, Hoekstra T, van Munster E, Verschuren O, Visser-Meily A, Kwakkel G; TREFAMS-ACE study group.

Arch Phys Med Rehabil. 2016 Nov;97(11):1887-1894.e1. doi: 10.1016/j.apmr.2016.04.019. Epub 2016 May 24.

PMID:
27233157
8.

More on PML in Patients Treated with Dimethyl Fumarate. Author reply.

Murk JL, Nieuwkamp DJ, van Oosten BW.

N Engl J Med. 2016 Jan 21;374(3):296. doi: 10.1056/NEJMc1512228. No abstract available.

PMID:
26798868
9.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

PMID:
26369555
10.

PML in Patients Treated with Dimethyl Fumarate.

Nieuwkamp DJ, Murk JL, van Oosten BW.

N Engl J Med. 2015 Aug 6;373(6):584. doi: 10.1056/NEJMc1506151. No abstract available.

11.

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.

Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP; PML in Dutch MS Patients Consortium.

N Engl J Med. 2015 Apr 9;372(15):1474-6. doi: 10.1056/NEJMc1413724. No abstract available.

12.

Reliability and responsiveness of cardiopulmonary exercise testing in fatigued persons with multiple sclerosis and low to mild disability.

Heine M, van den Akker LE, Verschuren O, Visser-Meily A, Kwakkel G; TREFAMS-ACE Study Group.

PLoS One. 2015 Mar 19;10(3):e0122260. doi: 10.1371/journal.pone.0122260. eCollection 2015.

13.

[Progressive cognitive disturbances in a 17-year-old boy].

Hepp DH, van Dijk K, Stam CJ, van Oosten BW, Foncke EM.

Ned Tijdschr Geneeskd. 2015;159:A8490. Dutch.

PMID:
25761293
14.

Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?

Malekzadeh A, Van de Geer-Peeters W, De Groot V, Teunissen CE, Beckerman H; TREFAMS-ACE Study Group.

Dis Markers. 2015;2015:758314. doi: 10.1155/2015/758314. Epub 2015 Jan 19.

15.

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.

Wijburg MT, van Oosten BW, Murk JL, Karimi O, Killestein J, Wattjes MP.

J Neurol. 2015 Jan;262(1):65-73. doi: 10.1007/s00415-014-7530-5. Epub 2014 Oct 9. Review.

PMID:
25297924
16.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9.

PMID:
25205744
17.

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30.

PMID:
25078275
18.

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J.

J Neurol. 2014 Jun;261(6):1139-43. doi: 10.1007/s00415-014-7336-5. Epub 2014 Apr 6.

PMID:
24705790
19.

Author response.

Wattjes MP, Visser F, van Oosten BW.

Neurology. 2013 Jul 23;81(4):403. No abstract available.

PMID:
24044116
20.

Case reports of PML in patients treated for psoriasis.

van Oosten BW, Killestein J, Wattjes MP.

N Engl J Med. 2013 Sep 12;369(11):1081-2. doi: 10.1056/NEJMc1307680. No abstract available.

PMID:
24040654
21.

The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme.

Beckerman H, Blikman LJ, Heine M, Malekzadeh A, Teunissen CE, Bussmann JB, Kwakkel G, van Meeteren J, de Groot V; TREFAMS-ACE study group.

Trials. 2013 Aug 12;14:250. doi: 10.1186/1745-6215-14-250.

22.

PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP.

N Engl J Med. 2013 Apr 25;368(17):1658-9. doi: 10.1056/NEJMc1215357. No abstract available. Erratum in: N Engl J Med. 2013 May 16;368(20):1950.

23.

What went wrong? The flawed concept of cerebrospinal venous insufficiency.

Valdueza JM, Doepp F, Schreiber SJ, van Oosten BW, Schmierer K, Paul F, Wattjes MP.

J Cereb Blood Flow Metab. 2013 May;33(5):657-68. doi: 10.1038/jcbfm.2013.31. Epub 2013 Feb 27. Review.

24.

Tumefactive multiple sclerosis lesions under fingolimod treatment.

Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW.

Neurology. 2012 Nov 6;79(19):2000-3. doi: 10.1212/WNL.0b013e3182735cb3. Epub 2012 Oct 3. No abstract available.

PMID:
23035065
25.

Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.

Malekzadeh A, de Groot V, Beckerman H, van Oosten BW, Blankenstein MA, Teunissen C.

Methods. 2012 Apr;56(4):508-13. doi: 10.1016/j.ymeth.2012.03.017. Epub 2012 Mar 24. Review.

PMID:
22465283
26.

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.

Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.

Neurology. 2011 Feb 8;76(6):574-6. doi: 10.1212/WNL.0b013e31820b7644. No abstract available.

PMID:
21300973
27.

No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study.

Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den Berg R, Uitdehaag BM, Polman CH, Barkhof F.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):429-35. doi: 10.1136/jnnp.2010.223479. Epub 2010 Oct 27.

PMID:
20980483
28.

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH.

Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074.

PMID:
20661928
29.

Steroid-responsive edema in CAA-related inflammation.

Daniëls R, Geurts JJ, Bot JC, Schonewille WJ, van Oosten BW.

J Neurol. 2009 Feb;256(2):285-6. doi: 10.1007/s00415-009-0136-7. Epub 2009 Jan 23. No abstract available.

PMID:
19159066
30.

Axonal neuropathy with prolonged sulphasalazine use.

Liedorp M, Voskuyl AE, Van Oosten BW.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):671-2.

PMID:
18799104
31.

[Immunomodulatory therapy in multiple sclerosis].

Uitdehaag BM, Jelles B, Killestein J, van Oosten BW, Polman CH.

Ned Tijdschr Geneeskd. 2007 Jun 23;151(25):1435; author reply 1435-6. Dutch. No abstract available.

PMID:
17668612
32.

The role of spinal cord imaging in the diagnosis of multiple sclerosis.

Nielsen JM, Barkhof F, van Oosten BW, Polman CH.

Nat Clin Pract Neurol. 2006 May;2(5):283-6; quiz 287.

PMID:
16932565
33.

Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG.

Cover KS, Vrenken H, Geurts JJ, van Oosten BW, Jelles B, Polman CH, Stam CJ, van Dijk BW.

Neuroimage. 2006 Feb 1;29(3):783-8. Epub 2005 Oct 14.

PMID:
16226894
34.

Effect of rimonabant on weight reduction and cardiovascular risk.

van Oosten B, Killestein J, Polman Ch.

Lancet. 2005 Jul 30-Aug 5;366(9483):368-9; author reply 369-70. No abstract available.

PMID:
16054933
35.

[Eyelid drooping: diagnosis on the basis of an algorithm].

van Oosten BW, de Langen CJ, Tissingh G, de Vries WA.

Ned Tijdschr Geneeskd. 2004 Sep 4;148(36):1753-8. Dutch.

PMID:
15495936
36.

[New diagnostic criteria for multiple sclerosis in clinical practice].

Van Oosten BW, Barkhof F, Polman CH.

Ned Tijdschr Geneeskd. 2004 Jul 17;148(29):1417-22. Dutch.

PMID:
15326641
37.

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

van Oosten BW, Killestein J, Mathus-Vliegen EM, Polman CH.

Mult Scler. 2004 Jun;10(3):330-1.

PMID:
15222701
38.

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.

van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Dräger AM, Adèr HJ, van Houwelingen JC, Barkhof F, Polman CH, Nagelkerken L.

Ann Neurol. 1999 Jun;45(6):695-703.

PMID:
10360761
39.

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.

van Walderveen MA, Truyen L, van Oosten BW, Castelijns JA, Lycklama à Nijeholt GJ, van Waesberghe JH, Polman C, Barkhof F.

Arch Neurol. 1999 Mar;56(3):345-51.

PMID:
10190826
40.

Choosing drug therapy for multiple sclerosis. An update.

van Oosten BW, Truyen L, Barkhof F, Polman CH.

Drugs. 1998 Oct;56(4):555-69. Review.

PMID:
9806103
41.

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Adèr HJ, Polman CH.

Arch Neurol. 1998 Jun;55(6):793-8.

PMID:
9626770
42.

Interleukin-2 therapy does not exacerbate multiple sclerosis.

van Oosten BW, Uitdehaag BM, Barkhof F, Hartung HP, Wagstaff J, Polman CH.

Neurology. 1997 Aug;49(2):633-4. No abstract available.

PMID:
9270618
43.

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH.

Neurology. 1997 Aug;49(2):351-7.

PMID:
9270561
44.
45.

TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.

Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS.

J Neuroimmunol. 1997 Feb;72(2):149-53.

PMID:
9042107
46.

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH.

Neurology. 1996 Dec;47(6):1531-4.

PMID:
8960740
47.

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Adèr HJ, Barkhof F.

Neurology. 1996 Dec;47(6):1469-76.

PMID:
8960729
48.

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

van Oosten BW, Lai M, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Hodgkinson S, Polman CH.

Mult Scler. 1996 Jul;1(6):339-42.

PMID:
9345413
49.

A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.

van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, Hartung HP, Adèr HJ, Polman CH.

J Neuroimmunol. 1996 May;66(1-2):49-55.

PMID:
8964913
50.

[Problems in weaning from artificial ventilation: 'motor neuron disease'].

van Oosten BW, van Gorp EC, Brandjes DP, van der Sande JJ.

Ned Tijdschr Geneeskd. 1996 Feb 3;140(5):264-7. Dutch.

PMID:
8643134

Supplemental Content

Loading ...
Support Center